Canada’s MedC to Develop Cannabis-Based Cancer Treatment Based on Israeli Technology

Cannabis treatment company MedC Biopharma Corporation of Canada announced earlier this month it has a global licensing agreement for a cannabis-based anti-cancer treatment developed at Israeli government research body Agricultural Research Organization (ARO), Volcani Center.

MedC, founded by Israeli brothers Avi and Guy Drori, also announced a partnership with a subsidiary of Israel-based Nextar Chempharma Solutions, an outsourcing company for drug development and manufacturing services, to develop treatments.

Volcani Center is preparing to submit the patents for the treatment of Cutaneous T cell lymphoma (CTCL), a type of immune system cancer that is classified by the U.S. Food and Drug Administration as an orphan disease. Clinical trials are planned for the beginning of 2019.